Unlocking New Possibilities for Drug Discovery and Cell Therapy
By the Combined Power of iPSC and Live Cell Bioimaging
About LumiSTAR Biotechnology, Inc.
LumiSTAR is developing a pipeline of innovative cell therapies based on induced pluripotent stem cell (iPSC) technology. These therapies have the potential to revolutionize the treatment of a wide range of diseases, including neurodegenerative diseases such as Parkinson’s and Alzheimer’s, CKD and cancer.
Other than cell therapy, the company also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs. The platform uses iPSC to create disease models for drug discovery and screening, allowing for more accurate and efficient identification of potential drug candidates.
Latest News and Events
01-Dec 2023
Check out our latest interview with Fortune Magazine/VoL about how LumiSTAR makes the incurable curable
15-Oct 2023
Congratulations to our CEO, Yu-Fen Chang, PhD, for being selected as one of the top 10 CEOs in biotechnology by Global Bio and Investment Magazine
11-Oct 2023
LumiSTAR attended 2023 BioJapan Exhibition in Yokohama
5-Oct 2023
LumiSTAR presented our latest work on iPSC 3D organoids using our LumiRDT technology in 2023 MD user meeting in Taiwan
27-July 2023
LumiSTAR organized a Focus Symposium with Molecular Devices, HCS Pharma at BIO Asia-Taiwan 2023.
1-May 2023
LumiSTAR won the 2nd prize in MedTech Pitch in 2023 SelectUSA investment Summit
Unique Triple Core Technology Platform
LumiSTAR’s triple core technology platform represents a sophisticated combination of iPSCs, viral vectors, and genetically encoded tools that enable the provision of stem cell solutions for both drug discovery and cell therapy.
iPSC
Differentiated cells for drug discovery and therapeutics
Viral Vectors
Installing genetically encoded tools inside cells, allowing for labeling, measurement, and therapeutic purposes
Genetically Encoded Tools
Allowing for real-time bioimaging on cellular dynamics for high-content and high-throughput screening
Management Team
Yu-Fen Chang, PhD
With 15+ years experience in bioimaging, iPSC technology and regenerative medicine.
Min-Wen Chung, PhD
Familiar with intellectual properties, regulations and production process
Catherine Tsai
With 15+ years experience in investment, venture capitals and corporate finance.
Shiu-Mei Wang, PhD
Chih-Chuan Su, PhD
Business Development
PhD in Physics, National Chung Hsing University, Taiwan